Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 9/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL16240132 | 0.96 | PTGER1 (0.47) | PTGER1SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL16319570 | 0.85 | SCN9A (0.51) | SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL16242182 | 0.80 | SCN9A (0.58) | SCN9AHTR2AHTR2C | |
| SCHEMBL364759 | 0.79 | MRGPRX4 (0.64) | SCN9ASCN5A | |
| SCHEMBL16319802 | 0.79 | SCN9A (0.63) | SCN9A | |
| SCHEMBL365276 | 0.78 | BCL2L1 (0.47) | SCN9ASCN5A | |
| SCHEMBL16240302 | 0.78 | MRGPRX4 (0.61) | SCN9ASCN5A | |
| SCHEMBL364527 | 0.75 | SCN9A (0.63) | SCN9ASCN5A | |
| Diethylamine SCHEMBL16239865 | 0.75 | MRGPRX4 (0.58) | SCN9ASCN5A | |
| Diethylamine SCHEMBL16239843 | 0.74 | CYP1A2 (0.46) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | PTGER1 372/4885SCN9A 16/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.